◆ Market Terminal AILook up a stock

Intellia Therapeutics, Inc. (NTLA)

Healthcare · Biotechnology · Small-cap · updated October 16, 2026

NOT A BUY TODAY
What this means. Intellia Therapeutics, Inc. is a weaker business by our measures, its shares look expensive compared with other stocks, and its share price has been doing well.
Value35
Quality38
Price trend76
Overall44
2027 of 2764rank among the US stocks we score (our core model buys the top 15)
27%of US stocks we score rank below it

Scores are 0 to 100 against every US stock we track; 50 is average. Recomputed after every US market close.

The business in numbers

Fiscal year to December 2025, from the company's annual filing with the SEC.

Salesyearly sales$67.7M
Sales growthchange from the year before+16.9%
Operating marginshare of sales left after running the business-651.7%
Net marginshare of sales kept as profit-609.9%
Free-cash-flow marginspare cash generated per $100 of sales-585.0%
Return on invested capitalprofit made on each $100 put into the business-51.9%
Return on equityprofit vs. shareholders' accounting value-61.5%
Change in share countnegative = the company is buying back its shares+9.6%

Insider trades, last 90 days

1 insider sold $91K on the open market.

Dulac Edward J IIIEVP, Chief Financial OfficerSoldJul 228,111 shat $11.25 · $91K

From Form 4 filings with the SEC. Open-market trades only. "Plan" = a sale set up in advance under a 10b5-1 plan, usually routine.

Higher-scoring in the same industry

Interactive lookupGet the Ledger every Monday

Not financial advice. Research and education only: the same view for everyone, with no regard to your circumstances. Past results do not predict future ones. Decide for yourself or with a licensed adviser. Terms · Privacy